BI-1808

• Description :

  BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8+ T cells[1].

• UNSPSC :

  12352203

• Target :

  TNF Receptor

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Purity :

  97.75

• Molecular Weight :

  (144.206 kDa)

• References & Citations :

  [1]Kristoffer Staahl Rohrberg1, et al. 757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab. J Immunother Cancer 2023;11 (Suppl 1) :A1–A1731

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2